WELCOME TO THIS WEBCAST

Spotlight on Emerging Immunotherapy Approaches and MET Inhibitors in Advanced NSCLC, brought to you by Ology Medical Education, was originally presented as a live, CME-certified 90-minute satellite symposium at the IASLC 2019 World Conference on Lung Cancer in Barcelona, Spain.

This UEMS-EACCME® accredited webcast, together with its transcript and downloadable slides from the live symposium will be hosted on this website for a period of 1 year.
Course opens: October 2019
Course expires: October 2020

Accreditation information:
Europe: 1 European CME credit (ECMEC®)
USA: The American Medical Association (AMA) has an agreement with the European Union of Medical Specialties to convert CME credit for select CME activities certified by the European Accreditation Council for Continuing Medical Education (EACCME), to AMA PRA Category 1 CreditTM. For more information please click here.

PROGRAMME

What is the current clinical status of novel immunotherapies in advanced NSCLC?

Luis Paz-Ares

Hospital 12 de Octubre
Madrid, Spain


What does the latest evidence reveal for emerging MET inhibitors?

Ross Camidge

University of Colorado Cancer Center
Denver, USA


Are we optimally prepared to provide personalized treatment strategies?

Martin Reck

LungenClinic Grosshansdorf
Grosshansdorf, Germany

 

REGISTER HERE

 

TARGET AUDIENCE
This programme is intended for oncologists, pulmonologists, pathologists and respiratory physicians involved in the diagnosis, treatment, and management of patients with advanced NSCLC.

EDUCATIONAL OBJECTIVES
After watching the webcast, you will be able to:

  • Summarize novel and emerging immunotherapy approaches and MET inhibitors, and evaluate their efficacy and safety in recent clinical trials
  • Discuss the potential role of these novel and emerging therapies in the treatment paradigm of patients with advanced NSCLC and the implications for clinical practice
  • Implement and assess new genomic profiling assays (e.g. liquid biopsy, NGS) that aid in identifying and treating patient subsets eligible for these novel and emerging therapies
  • Develop a care plan based on personalized treatment strategies to optimally manage patients receiving novel and emerging therapies, and to optimize the clinical utility of new diagnostic advances in detecting targetable mutations

 


Everett Vokes

University of Chicago
Chicago, IL, USA

EDUCATIONAL PARTNER
Ology Medical Education
info@ologyeducation.org